Cargando…

Profile of Secondary Bacterial and Fungal Infections in Hospitalized COVID-19 Patients in a Tertiary Care Centre

INTRODUCTION: SARS CoV-2, a novel corona virus, has emerged in December 2019. The COVID-19 associated mortality is documented in elderly with co morbidities. To have better insight on this issue, the secondary bacterial infections with multi-drug-resistant bacteria in COVID-19 patients need to be st...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhat K, Archana, Madi, Deepak, Bhat, Sevitha, Mary, Therese, Shenoy Mulki, Shalini, Kotian, Himani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527002/
https://www.ncbi.nlm.nih.gov/pubmed/36196428
http://dx.doi.org/10.2147/IDR.S378221
_version_ 1784800993180909568
author Bhat K, Archana
Madi, Deepak
Bhat, Sevitha
Mary, Therese
Shenoy Mulki, Shalini
Kotian, Himani
author_facet Bhat K, Archana
Madi, Deepak
Bhat, Sevitha
Mary, Therese
Shenoy Mulki, Shalini
Kotian, Himani
author_sort Bhat K, Archana
collection PubMed
description INTRODUCTION: SARS CoV-2, a novel corona virus, has emerged in December 2019. The COVID-19 associated mortality is documented in elderly with co morbidities. To have better insight on this issue, the secondary bacterial infections with multi-drug-resistant bacteria in COVID-19 patients need to be studied to evaluate the impact of these infections on the outcome. AIM AND OBJECTIVES: To determine the proportion of secondary infections in COVID-19 patients. To study the spectrum of pathogens and antibiogram of the bacteria isolated from secondary infections in such patients. To evaluate the co-existing co-morbidities, treatment and outcome in these patients. METHODOLOGY: The retrospective study was conducted in Departments of Medicine and Microbiology, KMC hospitals Attavara and Ambedkar circle, Mangaluru, including all the hospitalized microbiologically confirmed cases of SARS CoV-2 infection. Details pertaining to the study population were collected using a structured proforma. Descriptive data were entered in the form of mean, median and proportions. The categorical values were analyzed using Chi square test. Values of p < 0.05 were considered as statistically significant. RESULTS: Two hundred COVID-19 hospitalized patients were included.28 out of 200 patients (14%) studied developed secondary infections. The types of secondary infections were Respiratory infections (50%), blood stream infections (17%), UTI (14%), Rhinocerebral Zygomycosis (17%). The predominant organisms were Klebsiella pneumoniae (44%), Zygomycetes (17%). The rates of antibiotic resistance in Gram negative bacilli were 33% to Cefuroxime,25% to aminoglycosides and fluoroquinolones and 16% to carbapenems. The mortality of 42.8% was observed in patients with secondary infections. CONCLUSION: Close monitoring and follow up especially in high-risk group of severe COVID 19 patients is crucial for better management and outcome.
format Online
Article
Text
id pubmed-9527002
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-95270022022-10-03 Profile of Secondary Bacterial and Fungal Infections in Hospitalized COVID-19 Patients in a Tertiary Care Centre Bhat K, Archana Madi, Deepak Bhat, Sevitha Mary, Therese Shenoy Mulki, Shalini Kotian, Himani Infect Drug Resist Original Research INTRODUCTION: SARS CoV-2, a novel corona virus, has emerged in December 2019. The COVID-19 associated mortality is documented in elderly with co morbidities. To have better insight on this issue, the secondary bacterial infections with multi-drug-resistant bacteria in COVID-19 patients need to be studied to evaluate the impact of these infections on the outcome. AIM AND OBJECTIVES: To determine the proportion of secondary infections in COVID-19 patients. To study the spectrum of pathogens and antibiogram of the bacteria isolated from secondary infections in such patients. To evaluate the co-existing co-morbidities, treatment and outcome in these patients. METHODOLOGY: The retrospective study was conducted in Departments of Medicine and Microbiology, KMC hospitals Attavara and Ambedkar circle, Mangaluru, including all the hospitalized microbiologically confirmed cases of SARS CoV-2 infection. Details pertaining to the study population were collected using a structured proforma. Descriptive data were entered in the form of mean, median and proportions. The categorical values were analyzed using Chi square test. Values of p < 0.05 were considered as statistically significant. RESULTS: Two hundred COVID-19 hospitalized patients were included.28 out of 200 patients (14%) studied developed secondary infections. The types of secondary infections were Respiratory infections (50%), blood stream infections (17%), UTI (14%), Rhinocerebral Zygomycosis (17%). The predominant organisms were Klebsiella pneumoniae (44%), Zygomycetes (17%). The rates of antibiotic resistance in Gram negative bacilli were 33% to Cefuroxime,25% to aminoglycosides and fluoroquinolones and 16% to carbapenems. The mortality of 42.8% was observed in patients with secondary infections. CONCLUSION: Close monitoring and follow up especially in high-risk group of severe COVID 19 patients is crucial for better management and outcome. Dove 2022-09-28 /pmc/articles/PMC9527002/ /pubmed/36196428 http://dx.doi.org/10.2147/IDR.S378221 Text en © 2022 Bhat K et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bhat K, Archana
Madi, Deepak
Bhat, Sevitha
Mary, Therese
Shenoy Mulki, Shalini
Kotian, Himani
Profile of Secondary Bacterial and Fungal Infections in Hospitalized COVID-19 Patients in a Tertiary Care Centre
title Profile of Secondary Bacterial and Fungal Infections in Hospitalized COVID-19 Patients in a Tertiary Care Centre
title_full Profile of Secondary Bacterial and Fungal Infections in Hospitalized COVID-19 Patients in a Tertiary Care Centre
title_fullStr Profile of Secondary Bacterial and Fungal Infections in Hospitalized COVID-19 Patients in a Tertiary Care Centre
title_full_unstemmed Profile of Secondary Bacterial and Fungal Infections in Hospitalized COVID-19 Patients in a Tertiary Care Centre
title_short Profile of Secondary Bacterial and Fungal Infections in Hospitalized COVID-19 Patients in a Tertiary Care Centre
title_sort profile of secondary bacterial and fungal infections in hospitalized covid-19 patients in a tertiary care centre
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527002/
https://www.ncbi.nlm.nih.gov/pubmed/36196428
http://dx.doi.org/10.2147/IDR.S378221
work_keys_str_mv AT bhatkarchana profileofsecondarybacterialandfungalinfectionsinhospitalizedcovid19patientsinatertiarycarecentre
AT madideepak profileofsecondarybacterialandfungalinfectionsinhospitalizedcovid19patientsinatertiarycarecentre
AT bhatsevitha profileofsecondarybacterialandfungalinfectionsinhospitalizedcovid19patientsinatertiarycarecentre
AT marytherese profileofsecondarybacterialandfungalinfectionsinhospitalizedcovid19patientsinatertiarycarecentre
AT shenoymulkishalini profileofsecondarybacterialandfungalinfectionsinhospitalizedcovid19patientsinatertiarycarecentre
AT kotianhimani profileofsecondarybacterialandfungalinfectionsinhospitalizedcovid19patientsinatertiarycarecentre